3-<3-Oxo-7α-acetylthio-17β-hydroxy-4-androsten-17α-yl>-propionsaeure-lacton

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3-<3-Oxo-7α-acetylthio-17β-hydroxy-4-androsten-17α-yl>-propionsaeure-lacton
• 英文别名: Spironolacton；Aldacton；S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
• 化学式: C₂₄H₃₂O₄S
• 分子量: 416.582
• InChiKey: LXMSZDCAJNLERA-LJODGORCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  85.7
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Novel aldosterone antagonists and uses thereof
  申请人：Leonardi Amedeo

  公开号：US20070066580A1

  公开（公告）日：2007-03-22

  The present invention relates to novel compounds that are aldosterone receptor antagonists, to pharmaceutical compositions containing the aldosterone receptor antagonists, and to methods of treatment using the same.
• Oleaginous pharmaceutical and cosmetic foam
  申请人：Tamarkin Dov

  公开号：US20070292461A1

  公开（公告）日：2007-12-20

  The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.
• QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF
  申请人：TAMARKIN Dov

  公开号：US20080206161A1

  公开（公告）日：2008-08-28

  The present invention relates to an emulsion steroid composition as a foamable vehicle in which the vehicle is stable or stabilized by the presence of at least one quiesence agent; therapeutical kit containing such composition; to methods of treatment using such composition; to methods of enhancing the stability of such composition.
• SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT
  申请人：TAMARKIN Dov

  公开号：US20080292560A1

  公开（公告）日：2008-11-27

  A carrier, composition or foam formulation comprising; a silicone; about 25% to about 98% of a solvent selected from the group consisting of (1) a propylene glycol or derivative and (2) a polyethylene glycol (PEG) or derivative or mixtures thereof; 0% to about 48% of at least one secondary solvent; and an Accommodating Agent or Complex; and methods of treatment. A hygroscopic silicone in glycol containing composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and a therapeutic agent.
• Eplerenone Drug Substance Having High Phase Purity
  申请人：Barton Kathleen P.

  公开号：US20090149431A1

  公开（公告）日：2009-06-11

  A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.